A Combination of Autoantibodies to Cyclic Citrullinated Peptide (CCP) and HLA-DRB1 Locus Antigens is Strongly Associated with Future Onset of Rheumatoid Arthritis

Ewa Berglin; Leonid Padyukov; Ulf Sundin; Göran Hallmans; Hans Stenlund; Walther J van Venrooij; Lars Klareskog; Solbritt Rantapää Dahlqvist


Arthritis Res Ther. 2004;6(4) 

In This Article


This study has demonstrated that the presence of anti-CCP antibodies together with SE gene carriage is associated with a very high relative risk for future development of RA. This strong association with future development of RA in individuals positive for both SE and anti-CCP antibodies poses important questions relating to ethics and health policy. Thus, we shall need new strategies, both in research intended to understand factors that determine whether an individual with the presently identified risk factors will develop RA, and in clinical practice, where we may now possess a new means for analysing the risk of future development of RA in individuals who will have different needs or wishes to acquire such information.

This research article is open access, which means it is universally and freely accessible via the Arthritis Research & Therapy website, deposited in at least one widely and internationally recognized open access repository (such as PubMed Central), and the copyright rests with the authors.

To access research articles on related topics, visit http://arthritis-research.com/researcharticles.

Solbritt Rantapää Dahlqvist, solbritt.rantapaa.dahlqvist@medicin.umu.se

None declared.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: